Mosaic Family Wealth Partners LLC Makes New Investment in Novo Nordisk A/S (NYSE:NVO)

Mosaic Family Wealth Partners LLC acquired a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,760 shares of the company’s stock, valued at approximately $226,000.

A number of other institutional investors have also recently bought and sold shares of NVO. GQG Partners LLC lifted its holdings in shares of Novo Nordisk A/S by 654.6% during the 1st quarter. GQG Partners LLC now owns 3,633,064 shares of the company’s stock valued at $466,485,000 after buying an additional 3,151,584 shares during the last quarter. Capital International Investors increased its position in Novo Nordisk A/S by 22.3% in the 4th quarter. Capital International Investors now owns 7,114,931 shares of the company’s stock worth $736,121,000 after buying an additional 1,297,536 shares during the period. Acadian Asset Management LLC increased its position in Novo Nordisk A/S by 1,300.8% in the 1st quarter. Acadian Asset Management LLC now owns 1,244,128 shares of the company’s stock worth $159,703,000 after buying an additional 1,155,313 shares during the period. Price T Rowe Associates Inc. MD increased its position in Novo Nordisk A/S by 10.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 8,589,222 shares of the company’s stock worth $1,102,857,000 after buying an additional 823,036 shares during the period. Finally, International Assets Investment Management LLC increased its position in Novo Nordisk A/S by 10,359.2% in the 4th quarter. International Assets Investment Management LLC now owns 819,688 shares of the company’s stock worth $84,797,000 after buying an additional 811,851 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Price Performance

NVO stock traded down $4.97 during trading on Friday, hitting $127.49. The company had a trading volume of 4,774,033 shares, compared to its average volume of 3,918,008. The company has a fifty day moving average price of $138.21 and a two-hundred day moving average price of $129.20. The company has a current ratio of 0.70, a quick ratio of 0.50 and a debt-to-equity ratio of 0.17. The company has a market cap of $572.12 billion, a P/E ratio of 43.96, a P/E/G ratio of 1.33 and a beta of 0.41. Novo Nordisk A/S has a fifty-two week low of $78.19 and a fifty-two week high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Thursday, May 2nd. The company reported $0.83 EPS for the quarter, beating the consensus estimate of $0.77 by $0.06. The business had revenue of $9.52 billion for the quarter, compared to analyst estimates of $9.23 billion. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. Equities research analysts expect that Novo Nordisk A/S will post 3.38 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on NVO shares. Argus boosted their price objective on Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research report on Monday, June 10th. BMO Capital Markets restated an “outperform” rating and set a $163.00 price objective on shares of Novo Nordisk A/S in a research report on Tuesday, June 25th. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Monday, July 1st. Finally, The Goldman Sachs Group started coverage on Novo Nordisk A/S in a research report on Thursday, May 30th. They set a “buy” rating and a $156.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Moderate Buy” and a consensus price target of $145.67.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.